VRAY - ViewRay MRIdian better than CT-guided system for prostate cancer in trial

• ViewRay ( NASDAQ: VRAY ) on Thursday said its MRIdian system was better than CT-guided system in reducing toxicity in Stereotactic Body Radiotherapy (SBRT) for localized prostate cancer.
• The company reported main goal data from a phase 3 trial called MIRAGE which was independently conducted by investigators at UCLA and compared MRIdian MRI-guided SBRT versus CT-guided SBRT for localized prostate cancer in 156 patients.
• The company said acute grade ?2 genitourinary (GU) toxicity rates were significantly lower in the MRI-guidance  group (24.4%), compared to CT-guidance (43.4%) group.
• In addition, rates of acute grade ?2 gastrointestinal (GI) toxicity were also significantly lower in the MRI group (0.0%), versus 10.5% in the CT group.
• On multivariable analysis, which controls for differences in the use of hydrogel spacer, prostate size, and baseline urinary symptoms, the MRI-guidance group was linked with a 60% reduction in odds of grade ?2 GU toxicity, according to the company.
• ViewRay noted that were improvements in multiple patient-reported outcomes, such as urinary symptoms, bowel-related quality of life, for those in the MRI group, compared to the CT group.

For further details see: